We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Evotec Offers Agilent’s RapidFire/MS Screening for Pharmaceutical Drug Discovery"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

RapidFire, a robust, in-line solid phase extraction technology enables ultrafast, direct analysis of native compounds for a wide variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec is the first Pharmaceutical Contract Research Organisation in Europe to offer these services. The Evotec facility in Hamburg will be equipped with state-of-the-art technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.

“Evotec is the ideal partner for Agilent Technologies as we expand this industry-leading platform into the European Contract Research market,” said Gustavo Salem, Agilent Vice President and General Manager, Biological Systems Division. “Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard Mass Spectrometry platforms.”